Standout Papers

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung ... 2013 2026 2017 2021 372
  1. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial (2013)
    Marina Chiara Garassino, Olga Martelli et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 6 from Science/Nature 74 standout
Sub-graph 1 of 21

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes
2024 Standout
2 intermediate papers

Works of Flavia Longo being referenced

Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer
2016
Development of a prediction model and risk score for procedure-related complications in patients undergoing percutaneous computed tomography-guided lung biopsy
2015

Author Peers

Author Last Decade Papers Cites
Flavia Longo 976 891 409 71 2.0k
Alessandra Fabbri 1024 731 365 62 2.0k
Audrey Mauguen 753 493 314 108 2.0k
Michele Aieta 1173 975 587 115 2.2k
Sandra J. Strauss 1230 1404 395 91 2.9k
Deirdre Jill Cohen 719 428 293 92 1.6k
Marie Christine Aubry 1238 1390 365 99 2.8k
Makiko Itami 612 529 310 86 1.6k
Robert S. Lavey 718 490 364 52 2.4k
Meghan J. Mooradian 1702 1145 277 67 2.5k
Kaitlin M. Woo 1317 1175 153 66 2.6k

All Works

Loading papers...

Rankless by CCL
2026